Several vaccine companies in the COVID-19 outbreak rejoiced

:COVID-19 vaccine manufacturers are expected to split the $38 billion market. The biggest winners are likely to be Pfizer and its partner BioNTech, the first to market the mRNA vaccine.Pfizer expects to sell $15 billion of COVID-19 vaccines with BioNTech in 2021. Pfizer was the first company to license the COVID-19 vaccine in developed countries. By the end of January 2021, Pfizer had delivered 65 million doses of vaccines worldwide, expected to supply 200 million doses to the United States by the end of May, and said it could produce 2 billion doses of vaccines worldwide by 2021.Meanwhile, Moderna, a rival to Pfizer's mRNA vaccine, has received significant funding from its COVID-19 vaccine, mRNA-1273. As of mid-January, Moderna had received $11.7 billion in advance orders for vaccines from governments and organizations, and the company was negotiating more deals. Stephane Bancel, Moderna's chief executive, said in an interview that the company could join the ranks of the largest vaccine makers this year in terms of revenue. A year ago, Moderna didn't have any approved products.In addition to Pfizer and Modelna, analysts expect billions of dollars in opportunities for AstraZeneta, Johnson and Johnson andNovax in 2021.Now, however, nonprofits are pushing Pfizer and Modelna, as well as other pharmaceutical companies such as Eli Lilly, Gilead, Merck and Co., and Regeneron, to provide information about their drug and vaccine pricing decisions on the grounds that they all have federal funds to supply, develop or scale up production.

:GlaxoSmithKline GSK predicts that COVID-19 immunization campaigns could delay vaccination of its shingrix vaccine by several months. Shingrix has been a major driver of GSK's sales growth. In 2020, Shingrix achieved sales of $2.71 billion, a marked slowdown from an 11% year-on-year increase, and sales of the product more than doubled in 2019.The blockade imposed by COVID-19 has led to a sharp reduction in vaccination numbers, and GSK expects Shingrix's outage in the U.S. to last at least until the second half of 2021 as the outbreak continues to rage. To make matters worse, governments' priority vaccination of COVID-19 vaccines could have a significant impact on all adult vaccinations, including Shingrix.The Centers for Disease Control and Prevention (CDC) currently recommends a minimum 14-day interval between vaccinations for COVID-19 and other vaccines, plus two doses of COVID-19 vaccine, and a window between injections that could delay vaccination of Shingrix by several months. The COVID-19 epidemic has more broadly damaged some of GSK's traditional vaccine businesses, such as the hepatitis vaccine. Back-to-school vaccinations in the United States have also been suspended because schools have delayed or canceled face-to-face classes. In 2020, vaccine franchise sales were $9.53 billion, down 2% year-on-year. GSK expects sales in the sector to be flat or maintain a low single-digit percentage point increase in 2021 if vaccination rates pick up in the second half of the year. (Shanghai Cozhikang
)